Population Pharmacokinetics of ABT-806, an Investigational Anti-Epidermal Growth Factor Receptor (EGFR) Monoclonal Antibody, in Advanced Solid Tumor Types Likely to Either Over-Express Wild-Type EGFR or Express Variant III Mutant EGFR

Clinical Pharmacokinetics

Volumn 54, Issue 10, 2015, Pages 1071-1081

  Sharma, Shringi ^a   Mittapalli, Rajendar K ^a   Holen, Kyle D ^a   Xiong, Hao ^a  

^a ABBVIE INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABT 806; ALANINE AMINOTRANSFERASE; ALBUMIN; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CREATININE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG; ABT-806; EGFR PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR VIII;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BODY SURFACE; BODY WEIGHT; CANCER PATIENT; COMPARTMENT MODEL; CONCENTRATION AT STEADY-STATE; CREATININE CLEARANCE; DELETION MUTANT; DRUG BLOOD LEVEL; DRUG ELIMINATION; ELIMINATION HALF-LIFE; FEMALE; HUMAN; LEAN BODY WEIGHT; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MINIMUM PLASMA CONCENTRATION; OPEN STUDY; PHASE 1 CLINICAL TRIAL (TOPIC); PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; SOLID TUMOR; VOLUME OF DISTRIBUTION; ANTAGONISTS AND INHIBITORS; BLOOD; CLINICAL TRIAL; DOSE RESPONSE; GENETICS; IMMUNOLOGY; INTRAVENOUS DRUG ADMINISTRATION; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; NEOPLASMS; PHASE 1 CLINICAL TRIAL; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; BODY WEIGHT; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; NEOPLASMS; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84942504839     PISSN: 03125963     EISSN: 11791926     Source Type: Journal    
DOI: 10.1007/s40262-015-0258-2     Document Type: Article

References (14)

1. Dassonville O, Bozec A, Fischel JL, Milano G. EGFR targeting therapies: monoclonal antibodies versus tyrosine kinase inhibitors. Similarities and differences. Crit Rev Oncol Hematol. 2007;62:53–61.
2. Li T, Perez-Soler R. Skin toxicities associated with epidermal growth factor receptor inhibitors. Target Oncol. 2009;4:107–19.
3. AbbVie. A study of ABT-806 in subjects with advanced solid tumor types [ClinicalTrials.gov identifier NCT01255657]. US National Institutes of Health, ClinicalTrials.gov. http://www.clinicaltrials.gov. Accessed.
4. AbbVie. An evaluation of the biodistribution and imaging characteristics of ABT-806i (111In-ABT-806) in subjects with advanced solid tumor types [ClinicalTrials.gov identifier NCT01472003]. US National Institutes of Health, ClinicalTrials.gov. http://www.clinicaltrials.gov. Accessed.
5. AbbVie. Evaluating the safety and pharmacokinetics of ABT-414 for subjects with glioblastoma multiforme [ClinicalTrials.gov identifier NCT01800695]. US National Institutes of Health, ClinicalTrials.gov. http://www.clinicaltrials.gov. Accessed.
6. AbbVie. A study of ABT-414 in subjects with solid tumors [ClinicalTrials.gov identifier NCT01741727]. US National Institutes of Health, ClinicalTrials.gov. http://www.clinicaltrials.gov. Accessed.
7. Mathijssen RHJ, de Jong FA, Loos WJ, van der Bol JM, Verweij J, Sparreboom A. Flat-fixed dosing versus body surface area based dosing of anticancer drugs in adults: does it make a difference? Oncologist. 2007;12:913–23.
8. Tan AR, Moore DF, Hidalgo M, Doroshow JH, Poplin EA, Goodin S, et al. Pharmacokinetics of cetuximab after administration of escalating single dosing and weekly fixed dosing in patients with solid tumors. Clin Cancer Res. 2006;12:6517–22.
9. Dirks NL, Meibohm B. Population pharmacokinetics of therapeutic monoclonal antibodies. Clin Pharmacokinet. 2010;49:633–59.
10. Fasanmade AA, Adedokun OJ, Ford J, Hernandez D, Johanns J, Hu C, et al. Population pharmacokinetic analysis of infliximab in patients with ulcerative colitis. Eur J Clin Pharmacol. 2009;65:1211–28.
11. Zhu Y, Hu C, Lu M, Liao S, Marini JC, Yohrling J, et al. Population pharmacokinetic modeling of ustekinumab, a human monoclonal antibody targeting IL-12/23p40, in patients with moderate to severe plaque psoriasis. J Clin Pharmacol. 2009;49:162–75.
12. Müller C, Murawski N, Wiesen MHJ, Held G, Poeschel V, Zeynalova S, et al. The role of sex and weight on rituximab clearance and serum elimination half-life in elderly patients with DLBCL. Blood. 2012;119:3276–84.
13. Wang DD, Zhang S, Zhao H, Men AY, Parivar K. Fixed dosing versus body size-based dosing of monoclonal antibodies in adult clinical trials. J Clin Pharmacol. 2009;49:1012–24.
14. Bai S, Jorga K, Xin Y, Jin D, Zheng Y, Damico-Beyer LA, et al. A guide to rational dosing of monoclonal antibodies. Clin Pharmacokinet. 2012;51:119–35.